drugset / Trial / NCT06663072
Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase I, open-label study to assess the safety and preliminary efficacy of Fulvestrant in combination with 177Lu-DOTATATE for advanced pNETs.
Timeline
- Start
- 2024-12-13
- Primary completion
- 2026-11
- Completion
- 2026-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 177Lu-DOTATATE | Peptide | 3700 mbq | Intravenous |
| Subject | 177Lu-DOTATATE | Peptide | 7400 mbq | Intravenous |
| Subject | Fulvestrant | Small molecule | 500 mg | Intramuscular |